Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Preiningerova, JL; Baumhackl, U; Csepany, T; Czaplinski, A; Deisenhammer, F; Derfuss, T; Fabjan, TH; Fazekas, F; Fuchs, S; Havrdova, E; Ledinek, AH; Illes, Z; Jazbec, SS; Klimova, E; Komoly, S; Kurca, E; Linnebank, M; Lisy, L; Mares, J; Prochazkova, L; Csilla, R; Szilasiova, J; Stourac, P; Talab, R; Turcani, P; Vachova, M; Vecsei, L; Vodusek, D; Zapletalova, O; Berger, T.
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
CNS Neurosci Ther. 2013; 19(5):302-306
Doi: 10.1111/cns.12101
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Fuchs Siegrid
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management. © 2013 Blackwell Publishing Ltd.
- Find related publications in this database (using NLM MeSH Indexing)
- 4-Aminopyridine - adverse effects 4-Aminopyridine - pharmacology 4-Aminopyridine - therapeutic use
- Chemistry, Pharmaceutical -
- Clinical Trials, Phase III as Topic -
- Dose-Response Relationship, Drug -
- Humans -
- Multiple Sclerosis - drug therapy
- Potassium Channel Blockers - therapeutic use
- Practice Guidelines as Topic -
- Find related publications in this database (Keywords)
- Aminopyridines
- Fampridine
- Multiple sclerosis
- Walking